July 19, 2007 / 5:57 PM / 12 years ago

Novartis wins EU backing for Galvus, 2 other drugs

LONDON, July 19 (Reuters) - Novartis AG’s NOVN.VX experimental diabetes drug Galvus has been recommended for approval in Europe, lifting prospects for a medicine that faces a lengthy delay in getting to market in the United States.

Thursday’s decision by a committee of experts at the European Medicines Agency comes two days after Novartis said it would not be ready to resubmit Galvus to U.S. regulators until mid-2009, following a request for more safety data.

The agency’s Committee for Medicinal Products for Human Use (CHMP) also backed the Swiss group’s Exelon Patch, which delivers a treatment for Alzheimer’s disease through a skin patch, and once-yearly Aclasta for women with postmenopausal oesteoporosis.

Recommendations for marketing approval by the agency’s Committee for Medicinal Products for Human Use are normally endorsed by the European Commission within a couple of months.

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below